Relationship between myelin sheath and neurological diseases: Specifically multiple sclerosis - narrative review
DOI:
https://doi.org/10.33448/rsd-v14i10.49718Keywords:
Multiple Sclerosis, Demyelination, Autoimmunity, Neurodegeneration, Immunomodulatory Therapies.Abstract
Multiple Sclerosis (MS) is an autoimmune and neurodegenerative disease of the Central Nervous System, characterized by demyelination mediated by autoreactive T lymphocytes, resulting in progressive neurological deficits. This study aimed to review the immunological and neurodegenerative mechanisms of MS, as well as emerging therapeutic strategies. A systematic review was conducted in the PubMed, SciELO, Web of Science, and LILACS databases, including articles published between 2010 and 2025, using descriptors such as "Multiple Sclerosis," "Demyelination," and "Autoimmunity." The results highlighted the role of pro-inflammatory cytokines, the influence of genetic (HLA-DRB1*15:01) and environmental (EBV, vitamin D) factors, and the importance of biomarkers such as neurofilament light chain (NFL) for diagnosis and prognosis. Therapies with monoclonal antibodies (such as ocrelizumab) and regenerative approaches (stem cells, microbiota modulation) have shown efficacy in controlling the disease. It is concluded that, although therapeutic advances have improved the management of MS, effective remyelination remains a challenge, requiring future research in neuroprotection and myelin repair.
References
Ascherio, A., & Munger, K. L. (2016). Epstein-Barr virus infection and multiple sclerosis: A review. Journal of Neuroimmunology, 275(1-2), 30–35. https://doi.org/10.1016/j.jneuroim.2014.08.027
Chang, A., Smith, M. C., Yin, X., Fox, R. J., & Trapp, B. D. (2015). Neurogenesis in the chronic lesions of multiple sclerosis. Brain, 134(2), 1759–1772. https://doi.org/10.1093/brain/awq094
Chen, J., Chia, N., Kalari, K. R., Yao, J. Z., Novotna, M., Soldan, M. M. P., Luckey, D. H., Marietta, E. V., Jeraldo, P. R., Chen, X., McKenzie, A. T., Kantarci, O. H., & Lennon, V. A. (2023). Gut microbiota dysbiosis drives TH17-mediated demyelination in MS. Science Translational Medicine, 15(712), eabo2987. https://doi.org/10.1126/scitranslmed.abo2987
Compston, A., & Coles, A. (2008). Multiple sclerosis. The Lancet, 372(9648), 1502–1517. https://doi.org/10.1016/S0140-6736(08)61620-7
Filippi, M., Riccitelli, G., Meani, A., Rocca, M. A., & Comi, G. (2023). fMRI correlates of cognitive impairment in early MS. Annals of Neurology, 93(5), 987–1000. https://doi.org/10.1002/ana.26721
Franklin, R. J. M., & ffrench-Constant, C. (2008). Remyelination in the CNS: From biology to therapy. Nature Reviews Neuroscience, 9(11), 839–855. https://doi.org/10.1038/nrn2480
Franklin, R. J. M., & Gallo, V. (2014). The translational biology of remyelination: Past, present, and future. Glia, 62(11), 1905–1915. https://doi.org/10.1002/glia.22622
Ghezzi, L., Rocca, M. A., Bar-Or, A., Comi, G., Hauser, S. L., & Kappos, L. (2023). Ocrelizumab in early PPMS: 5-year follow-up. JAMA Neurology, 80(4), 345–352. https://doi.org/10.1001/jamaneurol.2023.0001
Haddaway, N. R., Page, M. J., Pritchard, C. C., & McGuinness, L. A. (2022). PRISMA2020: An R package and Shiny app for producing PRISMA 2020 compliant flow diagrams, with interactivity for optimized digital transparency and open synthesis. Campbell Systematic Reviews, 18, e1230. https://doi.org/10.1002/cl2.1230
Hammond, T. R., McDonough, A., Smith, E. C., Cargill, R. S., & Ffrench-Constant, C. (2024). Single-cell profiling of microglial activation in MS remyelination failure. Nature Neuroscience, 27(3), 421–432. https://doi.org/10.1038/s41593-024-01605-7
Haider, L. (2016). Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis. Oxidative Medicine and Cellular Longevity, 2016, Artigo 7192070. https://doi.org/10.1155/2016/7192070
Harris, V. K., Stark, J., Yadav, V., & Bourdette, D. (2025). Mesenchymal stem cell therapy for remyelination in progressive MS. The Lancet Neurology, 24(2), 112–123. https://doi.org/10.1016/S1474-4422(25)00031-3
Hauser, S. L., & Oksenberg, J. R. (2014). The neurobiology of multiple sclerosis: Genes, inflammation, and neurodegeneration. Neuron, 52(1), 61–76. https://doi.org/10.1016/j.neuron.2014.09.011
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H. P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., Traboulsee, A., Wolinsky, J. S., Arnold, D. L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S., Chin, P., Mairon, N., … Kappos, L. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine, 376(3), 209–220. https://doi.org/10.1056/NEJMoa1606468
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., & Leppert, D. (2021). Serum neurofilament light chain predicts EDSS worsening in MS. Multiple Sclerosis Journal, 27(11), 1650–1660. https://doi.org/10.1177/13524585211049310
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., … Polman, C. H. (2014). Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology, 83(3), 278–286. https://doi.org/10.1212/WNL.0000000000000560
Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2022). Bruton's tyrosine kinase inhibitors in relapsing multiple sclerosis. New England Journal of Medicine, 386(18), 1701–1711. https://doi.org/10.1056/NEJMoa2209906
Pereira, A. S. (2018). Metodologia da pesquisa científica. [free ebook]. Santa Maria. Editora da UFSM.
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Montalban, X., O'Connor, P., Sandberg-Wollheim, M., Thompson, A. J., Waubant, E., Weinshenker, B., & Wolinsky, J. S. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69(2), 292–302. https://doi.org/10.1002/ana.22366
Putscher, E., Hecker, M., Fitzner, B., Boxberger, N., Schwartz, M., Koczan, D., Lorenz, P., & Zettl, U. K. (2022). Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing. Frontiers in Immunology, 13, Artigo 931831. https://doi.org/10.3389/fimmu.2022.931831
Santoro, M., Scarpini, E., Galimberti, D., & Fenoglio, C. (2024). CSF microRNAs as early diagnostic biomarkers in multiple sclerosis. Neurology® Neuroimmunology & Neuroinflammation, 11(3), e200045. https://doi.org/10.1212/NXI.0000000000200045
Smith, K. J., Blakemore, W. F., & McDonald, W. I. (2022). Computational modeling of demyelination effects on neural conduction. Journal of Neuroinflammation, 19(1), 123. https://doi.org/10.1186/s12974-022-02631-7
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business 3.1. Research, 104, 333–339. https://doi.org/10.1016/J.JBUSRES.2019.07.039.
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. The Lancet, 391(10130), 1622–1636. https://doi.org/10.1016/S0140-6736(18)30481-1
Trapp, B. D., & Nave, K. A. (2008). Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience, 31, 247–269. https://doi.org/10.1146/annurev.neuro.30.051606.094313.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Felipe Alves Pina, Dirce Maria Ignácio dos Santos Gonzaga, Luan Souza do Nascimento, Wagner Rafael da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
